---
title: "Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292059906.md"
description: "In an Investigator-Sponsored Trial conducted by Memorial Sloan Kettering Cancer Center, it was found that 80% of participants receiving SER-155 attained a clinical response to diarrhea, which is a primary symptom of irEC, without the need for immunosuppressive treatment by Day 15."
datetime: "2026-07-08T11:02:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292059906.md)
  - [en](https://longbridge.com/en/news/292059906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292059906.md)
generator: "portal-rs"
---

# Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

In an Investigator-Sponsored Trial conducted by Memorial Sloan Kettering Cancer Center, it was found that 80% of participants receiving SER-155 attained a clinical response to diarrhea, which is a primary symptom of irEC, without the need for immunosuppressive treatment by Day 15.

### Related Stocks

- [MCRB.US](https://longbridge.com/en/quote/MCRB.US.md)

## Related News & Research

- [Seres Therapeutics to present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/297640933.md)
- [Seres Therapeutics explores partnerships to advance SER-155 development in immune checkpoint inhibitor-related enterocolitis](https://longbridge.com/en/news/292064839.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows](https://longbridge.com/en/news/297849557.md)
- [Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex](https://longbridge.com/en/news/298029888.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**